Gastrin I (human): Precision Tool for Gastric Acid Secretion Studies

Executive Summary: Gastrin I (human) is an endogenous peptide hormone that selectively activates cholecystokinin 2 (CCK2) receptors on gastric parietal cells, triggering proton pump-mediated acid secretion (APExBIO product description). The peptide enables reproducible, high-fidelity modeling of gastric acid secretion pathways in vitro, supporting both basic and translational gastrointestinal research (Saito et al., 2025). APExBIO's B5358 product offers ≥98% purity, validated by HPLC and mass spectrometry. The peptide is insoluble in water, but dissolves at ≥21 mg/mL in DMSO and should be stored at -20°C. Integration with hiPSC-derived intestinal models advances the study of human-specific gastrointestinal physiology and pharmacokinetics (Saito et al., 2025).

Biological Rationale

Gastrin I (human) is an endogenous hormone that orchestrates gastric acid secretion by binding the CCK2 receptor, primarily expressed on gastric parietal cells. This regulatory axis is central to maintaining stomach pH and digestive function. Dysregulation of this pathway is linked to gastrointestinal disorders, including peptic ulcer disease and Zollinger-Ellison syndrome. In vitro, the use of human Gastrin I peptide enables direct, receptor-specific interrogation of acid secretion mechanisms, bypassing species differences inherent to animal models (Saito et al., 2025). The peptide's role as a gastric acid secretion regulator underpins its utility in both mechanistic and translational research workflows.

Mechanism of Action of Gastrin I (human)

Upon administration, Gastrin I (human) binds selectively to the CCK2 receptor (also known as the gastrin receptor) located on the basolateral membrane of gastric parietal cells. This engagement activates G-protein-coupled intracellular signaling cascades, leading to increased cyclic AMP and calcium influx. The downstream effect is the activation of H+/K+ ATPase proton pumps, resulting in augmented secretion of gastric acid into the stomach lumen (APExBIO). This pathway is highly conserved in humans and is a critical target for in vitro modeling of gastric acid secretion and investigation of acid-related diseases.

Evidence & Benchmarks

• Gastrin I (human) triggers robust, dose-dependent acid secretion in primary human gastric epithelial models, confirming its role as a selective CCK2 receptor agonist (Saito et al., 2025).
• In hiPSC-derived intestinal organoids, Gastrin I exposure accurately recapitulates physiological proton pump activation, as measured by luminal acidification and transporter expression (Saito et al., 2025).
• The APExBIO B5358 product is supplied as a white lyophilized solid with a molecular weight of 2098.22 Da and a chemical formula of C97H124N20O31S (APExBIO).
• Purity assessments by HPLC and mass spectrometry ensure a typical purity of ≥98%, supporting reproducible results in gastric acid secretion pathway research (APExBIO).
• Compared to animal and immortalized cell models, human Gastrin I peptide enables more clinically relevant data when integrated with hiPSC-derived gastrointestinal systems (Saito et al., 2025).

For an expanded mechanistic breakdown, see this review, which details CCK2 receptor signaling and contrasts rodent versus human models. This article extends those insights by providing updated protocol parameters and benchmarking against the latest hiPSC-organoid workflows.

Applications, Limits & Misconceptions

Human Gastrin I peptide is widely adopted as a gastric acid secretion assay reagent in studies of gastrointestinal physiology, pharmacokinetics, and acid-related disease modeling. Its specificity for the CCK2 receptor enables controlled activation of the gastric acid secretion pathway in both traditional cell cultures and advanced organoid systems.

• Integrates seamlessly with hiPSC-derived intestinal organoids for pharmacokinetic and transporter function studies (Saito et al., 2025).
• Enables high-fidelity modeling of proton pump activation and downstream signaling in human epithelial systems (internal article), extending previous benchmarks by focusing on clinical translatability.
• Supports investigations into gastrointestinal disorders, including hypergastrinemia syndromes and drug-induced acid modulation (internal article). This article clarifies the optimal use of Gastrin I in next-generation organoid workflows.

Common Pitfalls or Misconceptions

• Gastrin I (human) is not water- or ethanol-soluble; improper solvent selection (use DMSO at ≥21 mg/mL) leads to incomplete dissolution (APExBIO).
• The peptide is unstable in solution over time; prolonged storage after reconstitution can result in degradation and decreased activity (APExBIO).
• Animal models may not fully recapitulate human receptor pharmacology, highlighting the necessity of human-specific tools for translational research (Saito et al., 2025).
• Gastrin I (human) exclusively targets CCK2/Gastrin receptors, not CCK1 (cholecystokinin A) receptors (internal article), clarifying receptor selectivity for experimental design.
• It is not suitable for in vivo use as a therapeutic; its role is restricted to in vitro/ex vivo research (APExBIO).

Workflow Integration & Parameters

Protocol Parameters

• Solvent preparation: Dissolve Gastrin I (human) at concentrations ≥21 mg/mL in DMSO for stock solutions (APExBIO).
• Storage conditions: Store lyophilized peptide desiccated at -20°C; avoid repeated freeze-thaw cycles.
• Working solution: Prepare fresh dilutions in assay buffer immediately before use; do not store reconstituted solutions long-term.
• Recommended working concentration: Typical in vitro assays employ 1–100 nM range, titrated based on cell model and endpoint readout (Saito et al., 2025).
• Assay compatibility: Validated in gastric acid secretion assays, CCK2 receptor signaling studies, and hiPSC-derived intestinal organoid models.

For practical integration into advanced workflows, see the strategic guidance in this article, which elaborates on experimental design using hiPSC-derived organoid models and provides troubleshooting tips for maximizing data fidelity.

Conclusion & Outlook

Gastrin I (human), as provided by APExBIO, remains a gold-standard tool for dissecting gastric acid secretion and CCK2 receptor signaling in vitro. Its validated performance in hiPSC-derived organoid systems positions it as a cornerstone for next-generation gastrointestinal physiology studies and preclinical drug development. The integration of human Gastrin I peptide into organoid workflows enables the modeling of human-specific pharmacokinetics and disease mechanisms, addressing longstanding translational gaps in gastrointestinal disorder research (Saito et al., 2025). As protocols mature and new benchmarks emerge, the role of high-purity, well-characterized reagents such as the B5358 kit will only increase in importance for both mechanistic discovery and clinical translation.